NEW YORK (GenomeWeb News) – Indian contract research organization GVK Biosciences said on Monday that it has entered into a drug screening deal with the Moulder Center for Drug Discovery Research at Temple University.
The multi-year agreement calls for GVK Bio to validate targets and identify and optimize small molecules in specific therapeutic areas, such as cardiovascular, metabolic, and central nervous system disorders.
It also will be responsible for reagent generation, assay development, and establishing the screening cascade for lead identification and optimization. The partners will jointly design the molecules for the program. The molecules will be optimized and progressed through lead optimization to pre-clinical candidate.
Financial terms of the alliance were not disclosed.